Mr. Chair, I'll note a number of areas. These changes allowed for multiple-site clinical trials, shortened review periods and the use of multiple investigators at these sites. They were really intended to enable, as the member noted, the attraction of clinical trials, of which we have over 100 now, which are associated with COVID vaccines and therapies.
On May 25, we also launched a consultation on clinical trials modernization to look at updating the regulatory framework across all product lines. This is building on some of the experience with the interim order, which was renewed in May.